Amgen Inc. is moving forward with a $650 million expansion of its U.S. manufacturing network to enhance production of cancer therapies, despite facing a class-action lawsuit related to a $10.7 billion tax liability. The company's stock performance remains resilient, posting a 6.1% year-to-date gain, as it navigates regulatory scrutiny and ongoing competition in the biotechnology sector. Recent analyst upgrades highlight optimism about Amgen's growth potential, even as the firm deals with legal pressures and adjusts its strategies in response to market dynamics and recent drug development outcomes.
Click a month on the chart to update the report below.
%20-%20USA%20-%20UNOCHA.svg&width=160)
